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Abstract
This chapter will introduce the clinician to the quickly expanding field of 
musculoskeletal-focused digital apps (MDA), with an eye towards helping the clini-
cian select and recommend MDAs for optimal patient care. MDAs are increasingly 
being used for physical therapy and rehabilitation, telehealth, pain management, 
behavioral health, and remote patient monitoring. The COVID-19 pandemic has 
vastly accelerated the adoption of telehealth and digital health apps by patients and 
clinicians, and the digital health field will only continue to expand as developers 
increasingly harness artificial intelligence (AI) and machine learning (ML) capa-
bilities, coupled with precision medicine capabilities that integrate personal health 
data tracking and genomics insights. Here we begin with an overview of several 
types of MDA, before discussing the epidemiology of musculoskeletal conditions 
and injuries, clinical considerations in selecting a digital health solution, payor 
reimbursement for digital apps, and regulatory oversight of digital health apps.
Keywords: digital health, telemedicine, physical therapy, musculoskeletal,  
artificial intelligence
1. Introduction
Digital health is a rapidly growing field. As of early 2019, there were over 318,000 
mobile health applications in different app stores--and that number itself doubled 
since 2015 as consumers increasingly used mobile apps to manage their health [1]. 
Popular mobile health apps include AI-powered health symptom checkers, clinical 
records management apps, remote patient monitoring tools, patient self-monitoring 
tools, rehabilitation programs, and apps for medical condition education and man-
agement. In fact, healthcare applications constitute the most popular smartphone 
activity. Currently, 90% of physicians use smartphone applications for medical 
records, communication with their teams and for clinical content like UptoDate [2]. 
Over 75% of the largest health systems now offer mobile applications focused on 
patient engagement [3]. The global mobile health market is growing and is expected 
to reach $111 billion by 2025 with fitness constituting $50B in the US health market. 
The current COVID-19 Pandemic will accelerate the adoption and will further 
increase the adoption and growth [4].
An American Medical Association survey found that physicians’ use of technol-
ogy to provide televisits or virtual visits doubled from 2016 to February 2020, with 
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Kaia Health Multimodal Pain 
Therapy





Yes Yes Yes N/A Yes No Yes N/A
HBD 
International





N/A Yes N/A N/A Yes N/A Yes
Movement RX Mind-Body 
Connection 
Improvement
Yes Yes Yes N/A Yes Yes N/A Yes
PHZIO Media Early Prevention and 
Intervention (Thru 
PT)
N/A N/A N/A N/A N/A Yes N/A Yes
Airrosti Prevention, Recovery, 
and Education
N/A N/A Yes N/A Yes Yes N/A Yes
SimpleTherapy Personalized Pain 
Recovery
Yes N/A No N/A No Yes N/A N/A
Hinge Health Sensor-Guided 
Exercise Therapy
Yes N/A Yes N/A No Yes N/A Yes
Table 1. 
Digital Health Apps for Managing Musculoskeletal Pain and Functional Limitations [9].
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the COVID-19 pandemic, physician use of telemedicine has increased exponentially 
as digital technologies have become increasingly adopted by both physicians and con-
sumers. Physical therapist and physiotherapist adoption of musculoskeletal-focused 
digital apps (MDA) has likewise expanded exponentially [6]. Consumer adoption of 
telehealth increased from 11% of care visits in 2019 to 46% in May 2020, as provid-
ers scaled the offerings and are seeing 50 to 175 times the number of patients via 
telehealth compared to before. In 2019, the annual revenue of US telehealth vendors 
was $3 Billion with a big focus on the virtual urgent care segment. With new Centers 
for Medicare and Medicaid Services (CMS) policies being implemented during the 
crisis to expand the use of virtual care, up to $250 Billion of current US healthcare 
spend could potentially be virtualized [7]. Primary care and behavioral health have 
led in the number of virtual visits. The services/clinical models that have the greatest 
potential for virtual care include on demand virtual urgent care, office visits, home 
health services and home medication administration services [8].
In particular, the number of mobile medical apps for musculoskeletal condi-
tions and injury management is increasing exponentially as organizational health 
and wellness initiatives increasingly focus on pain management and holistic care. 
Table 1 provides an overview of features present in several MDAs on the market 
as of August 2020. The general purpose of these different musculoskeletal apps 
is to provide therapy on a large sale for patients with musculoskeletal disorders. 
The MDAs surveyed in this table have physical or mental exercise programs, and 
some have behavioral interventions such as mindfulness practice. Most apps also 
have learning modules to teach organizations and individuals how to stay safe and 
protect themselves from further issues.
The MDAs surveyed differ in their targeted goals and their approach to achieving 
their goals. For example, Kaia Health concentrates on using multiple approaches to 
minimize pain, whereas Movement RX focuses on strengthening the mind-body 
connection to reduce pain. Wellness Coaches places emphasis on a very personalized 
and face to face therapy program. And while many apps do not have physical hard-
ware, SimpleTherapy and Hinge Health use sensors that can be placed over joints to 
track progress and pain.
Moreover, most of the surveyed MDAs can be effectively used to improve 
population health, injury prevention and rehabilitation in large organizations and 
companies. The MDAs focus on individual health and progress, while also address-
ing how to prevent organizational ergonomic issues and manage musculoskeletal 
injury recovery.
2. Epidemiology of Musculoskeletal Conditions and Injuries
Musculoskeletal conditions continue to increase in incidence and prevalence, 
especially as the geriatric population grows, and organizations continue to have 
unremedied ergonomics issues. Musculoskeletal disorders are highly prevalent, 
yet frequently mismanaged and costly. Musculoskeletal injuries are also a top cost 
driver for employers, as no other chronic health condition causes more lost work-
days and more healthcare spend than musculoskeletal injuries [10]. Musculoskeletal 
lower back injury is the leading cause of disability both globally and in the U.S., and 
the number one reason for missing work [11]. In the U.S. alone, musculoskeletal 
lower back injuries result in more than 260 million lost workdays each year as well 
as significant healthcare and disability insurance costs [12]. 1 in 2 adults in the 
U.S. were diagnosed with musculoskeletal conditions in 2012. Despite the high 
prevalence of musculoskeletal conditions, 80% of patients do not receive evidence-
based care [13]. As detailed below, musculoskeletal pain continues to be frequently 
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mismanaged with opioid analgesics, and unnecessary surgery is frequently 
performed when physical therapy and rehabilitation would be more appropriate. 
Medical costs for imaging, diagnosis and treatment of musculoskeletal injuries and 
conditions continue to rise [14].
Musculoskeletal joint pain has significant impact on patient function and future 
health. Joint pain reduces physical activity, increases opioid use, impacts produc-
tivity, and leads to obesity [15]. Obesity in turn increases the risk for diabetes, 
heart disease, depression, and cancer [16].
Yet Musculoskeletal pain is frequently mismanaged with opioid analgesics. Even 
as warnings of an opioid crisis in the US have increased provider and patient aware-
ness of the dangers of opioid analgesics, opioids remain a commonly prescribed 
treatment for lower back musculoskeletal pain. The dangers of opioid analgesics are 
well known and include dependence, dangerous side effects including respiratory 
depression, fatality from drug overdose, and high incidence of concomitant illicit 
drug use [17]. Moreover, when used to treat new diagnoses of lower back pain, 
opioid analgesics result in longer recovery times, increased serious adverse events, 
and greater healthcare utilization (emergency room visits and hospitalizations) 
compared to non-opioid analgesics [18].
Likewise, patients frequently receive inappropriate surgery for musculoskeletal 
conditions. Studies have shown that approximately 66% of surgeries are avoidable 
[19]. Inappropriate surgery for musculoskeletal conditions comes with significant 
recovery times, lengthening the treatment period, increasing cost of care, and 
yielding poorer pain and functional outcomes relative to conservative management 
and physical therapy [20].
Musculoskeletal issues will continue to rise, especially as the geriatric population 
grows, ergonomic work situations are not well controlled in factories and ware-
houses, and medical costs for imaging, diagnosis and treatment continue to rise. 
Studies predict that by 2030, there will be a 500% increase in total knee replace-
ments [21], and a 200% increase in total hip replacements in 45- to 64-year-olds 
[22]. Likewise, studies project a 28% increase in spine surgeries by 2024 [23].
3. Critically Assessing Musculoskeletal Digital Apps
With increasing adoption of telehealth and digital solutions comes increasing 
demands on clinicians to recommend and use MDAs appropriately, while avoiding 
dangers and pitfalls. Here, we detail methods to assess the clinical effectiveness, the 
functionality, and the reliability of digital health solutions.
The landscape of digital health solutions on the Internet and app stores has been 
likened to the Wild West, given the inability of regulators to keep up with the explo-
sive growth of medical apps. A significant pitfall to avoid is apps that falsely claim 
to diagnose, prevent, or treat a disease or medical condition. Such claims require 
FDA review and approval prior to marketing, and digital apps have been pulled off 
the market for making false claims. For example, in 2011, an app developer claimed 
that the app could use the blue light emitted from a mobile device to cure acne. The 
Federal Trade Commission (FTC) intervened to prohibit marketing of the app, 
and the app was removed from app stores for failure to obtain regulatory approval 
[24]. For digital health apps that do not make diagnostic, prevention, or treatment 
claims, however, regulatory approval is not required. Absent fraud, such apps will 
not be removed from the digital marketplace. It is thus important for clinicians to be 
able to assess the utility of digital health solutions.
Two well-known entities that evaluate Internet resources are the Health on 
the Net Foundation (HON) and the Agency for Healthcare Research and Quality 
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(AHRQ ). HON published a HON Code of Conduct (HONcode) in 1996 that 
includes 8 principles for certifying information on health and medical websites. 
The 8 principles include Authority, Complementarity, Confidentiality, Attribution, 
Justifiability, Transparency, Financial Disclosure, and Advertising [25]. AHRQ 
proposed similar criteria, including credibility, content, disclosure, links, design, 
interactivity, and caveats [26]. Hanrahan et al. recommend applying similar criteria 
to the evaluation of digital health apps [27].
In assessing the clinical effectiveness of an intervention, the clinician will want 
to consider the types of study designs used to generate evidence of effectiveness 
[28]. Traditionally, randomized controlled trials are considered the gold standard 
in evidence assessment [29], followed by observational studies such as cohort, 
cross-sectional, and case-control studies, and ending with descriptive studies such 
as surveillance, surveys, and case reports [30]. However, a nuanced that takes into 
account the size of the study and the rigor of the study design, recognizes that large, 
well-designed observational studies can yield among the highest-quality clinical 
evidence. Moreover, observational studies offer evidence of clinical effectiveness 
under real-world conditions, in contrast with randomized trials, which may have 
restrictive inclusion and exclusion criteria and lack generalizability beyond the 
highly controlled experimental study settings [31]. A commonly used system of 
assessing the quality of evidence generated by medical studies is The Cochrane 
Collaboration’s GRADE approach [32].
MDAs vary widely with regard to functionality. By being aware of the different 
functions offered by different MDAs, the clinician can tailor recommendations 
to patients with different musculoskeletal monitoring or rehabilitation needs. As 
detailed in Table 1, some apps are more focused on pain management, while others 
are focused on restoring and improving physical function. Some apps include hard-
ware, such as EKG and heart rate sensors and sensors over joints to track movement. 
Other apps focus on behavioral interventions to address pain and help patients stay 
on track with physical therapy plans to address musculoskeletal injuries.
Evidence based exercise-therapy is another function offered by a number of 
digital vendors. From gathering detailed information on movement and activity 
and leveraging artificial Intelligence, digital apps can deliver personalized advice 
and exercise programs that adapt according to the progress made by the individual. 
Some apps focus on preventing the development of conditions and maintaining 
musculoskeletal health, including access to a comprehensive library of preventative 
exercise programs, including Pilates, yoga, stretching and strengthening options. 
TrackActive is a digital application that specializes in rehabilitation of musculoskel-
etal conditions and acts as virtual physio enabling people to assess and self-manage 
injuries and common conditions from home [33]. Based on the member profile, 
this application tracks members activities using different surveillance techniques 
and provides personalized recommendations. Telehealth apps that facilitate virtual 
second opinions for different musculoskeletal conditions are also increasingly being 
utilized [34].
Many digital apps now focus on musculoskeletal injury prevention in occupa-
tional settings. Musculoskeletal injuries are the largest single category of workplace 
injury and account for 28% of all occupational injuries [35]. Occupational health 
focused digital apps thus aim to reduce muscle, joint, tendon, ligament and nerve 
injuries/illnesses across the workforce to improve availability and productivity [36].
With 40% of all mobile apps related to healthcare, verifying accuracy of clini-
cal content and validating apps for intended clinical uses is critical. While assess-
ing the clinical benefit of MDA functions, it is important to review the available 
evidence. For example, one randomized controlled trial (n=215) concluded that an 
MDA that included behavioral interventions such as medication reminders, daily 
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surveys of symptoms and potential adverse effects, fared no better than usual care 
in reducing pain scores [37].
Mobile health apps for monitoring postoperative pain are another promising 
frontier for MDAs. Such digital apps can provide real time monitoring and symp-
tom management and can help improve self-management skills with post-operative 
pain. To alleviate pain, digital apps can provide appropriate distraction, relaxation, 
and guided imagery techniques. However, a critical review of digital apps focused 
on self-management of pain showed very limited involvement of healthcare special-
ists and limited evidence based self-learning content. Lalloo et al. found that of 10 
mobile applications meeting inclusion criteria, none provided social support, goal 
setting criteria, or had scientific evaluation or end users in their development [38]. 
Only 50% of the apps included a provider specialist in the development. There is 
accordingly a need to build comprehensive pain self-management, evidence based, 
personalized, AI-driven mobile applications.
When assessing an MDA’s functionality, the clinician will want to assess the 
MDA’s ability to not only improve subjective pain scores, but also to improve 
objectively quantifiable measures of disability function. The MDAs with high-
est likelihood of yielding clinical benefit are those whose efficacy on objective 
measures have been established in peer-reviewed studies [39]. For example, 
two smaller randomized controlled trials demonstrated efficacy of MDAs with 
respect to improving both knee and back pain and disability function [40, 41]. 
These beneficial impacts on both chronic musculoskeletal pain and disability 
function were subsequently confirmed in a large 10,000 participant longitudinal 
cohort [42].
Moreover, some MDAs offer population health surveillance features that can 
be useful to health officers in organizations tracking the health of their workforce. 
While such features can be very useful in workforce injury surveillance and 
prevention, it is important to be aware of privacy issues when deploying such 
solutions in an organizational or work setting. In particular, the ability to lever-
age Artificial Intelligence (AI) focused digital health apps for population health 
surveillance have garnered critical attention during the COVID19 pandemic. Tools 
that track disease activity in real time include contact tracing applications that 
identify and track individuals who might have come in contact with an infected 
person. User consent is essential for the adoption and sustained growth of such 
digital health applications [43, 44].
Finally, in evaluating the utility of digital health apps, clinicians should also rec-
ognize app performance issues such as functionality, stability/reliability, and stage 
of development, which affect the usability of the app and the benefit to patients. 
The proliferation of digital health applications has led app developers to focus on 
functionality, stability, security, privacy, usability, reliability, and data accuracy. In 
evaluating performance of mobile apps, it is advisable to utilize a framework that 
evaluates each dimension of the application. We recommend a framework consist-
ing of rating domains and criteria for each domain. The domains are (1) Usability, 
which includes functionality, visualization, ease of install and use, multi-language 
support and ability to customize; (2) Content (Technical), which includes per-
formance, stability, interoperability, portability, bandwidth and application size; 
(3) Content (Health), which includes quality, presentation and validation of the 
information, literacy level, measurement and interpretation of the information and 
potential for harm; (4) Security/privacy/compliance, which includes data authen-
tication, protection, tokenization, authentication and pro-active breach signaling; 
and (5) Transparency, which includes member consent, cost of the app and accu-
racy of the description in the app stores [45].
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4. Employer and Payor Reimbursement
The COVID-19 pandemic fueled rapid healthcare provider adoption of tele-
health, as social distancing measures were implemented and government and 
commercial payors relaxed regulations and reimbursement requirements [46]. The 
transformation of care delivery in turn enabled consumers and providers to connect 
via virtual healthcare visits and associated modalities. The widespread adoption of 
telehealth has led both employers and payers to accelerate and look for innovative 
ways to reimburse for different digital health apps. For example, the recent $37 
Billion merger of telehealth leader Teladoc and digital chronic disease management 
company Livingo has set the precedent for rapid change in adoption of digital appli-
cations with payers and employers ready for embracing them as part of mainstream 
providers [47]. In the fragmented U.S. market, potential barriers remain in terms of 
who will pay, but payers are starting to cover digital apps.
The Decision Resources Group found that across healthcare executives in 
integrated health networks (IDNs), Medicaid managed care organizations (MCOs), 
and pharmacy benefits managers (PBMs), 25% said their organization provides 
coverage for digital therapeutics, and an additional 45% expressed interest in 
providing coverage. In a 2019 survey, the National Business Group on Health found 
that 25% of large self-funded employers are considering creating orthopedic centers 
of excellence by 2021 [48]. Moreover, 45% of orthopedic COE contracts are struc-
tured as bundled payments. Given the potential for clinical benefit and cost savings, 
employers and health insurance payors are increasingly reimbursing use of digital 
health apps.
5. FDA Regulation of Digital Health Apps
Products intended to diagnose, prevent, or treat disease must be approved 
by the FDA prior to marketing. FDA regulation of medical devices balances two 
competing goals: [1] promoting innovation and improvement in medical devices; 
and [2] ensuring that medical devices are safe and effective [49]. Accordingly, FDA 
classifies medical devices according to potential risk. Class I devices are low risk and 
subject to general controls, and examples include bandages and sunglasses. Class 
II devices are intermediate risk and are often approved subject to the abbreviated 
510(k) pathway, if the devices are able to rely on the prior approval of a similar 
device. Examples include pregnancy test kits, hearing aids, and powered wheel-
chairs. Class III devices require a premarket approval application (PMA) and are 
subject to full FDA review of safety and efficacy. Only 10% of medical devices fall 
in this category, and examples include implantable pacemakers, and high-frequency 
ventilators.
FDA has historically struggled to fit medical software and apps into the tradi-
tional medical device classification. In recent years, however, FDA has issued more 
detailed guidance informing app developers when digital health products will need 
to undergo regulatory review, and the requirements for regulatory approval [50]. 
FDA takes a risk-based approach to medical software and app regulation, focus-
ing on devices that could pose a risk to a patient’s safety if the device were not to 
function as intended. For example, software functions that transform the mobile 
platform into a regulated medical device by using attachments, display screens, or 
sensors—such as motion tracking sensors or EKG functionality—will be subject 
to regulation as a medical device [51]. Apps that perform patient-specific analysis 
and provide patient-specific diagnosis, or treatment recommendations, such as 
Environmental Health
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image-processing software and radiation therapy treatment planning software, will 
also be subject to close regulatory scrutiny. On the other hand, FDA intends to exer-
cise its discretion not to enforce regulations for lower risk apps that automate simple 
tasks for health care providers or help patients self-manage their disease without 
providing specific treatment suggestions. For example, FDA will not enforce its 
regulations on software functions that provide physicians easy access to the latest 
treatment guidelines, or software that coaches patients on the basics of conditions 
such as obesity or arthritis and provide strategies for weight reduction. Indeed, 
most digital health apps are not reviewed and cleared by FDA. In November 2013, 
only 100 of over 10,000 medical apps available on the marketplace were cleared by 
FDA [52].
To evaluate the clinical effectiveness and safety of software as a medical device, 
FDA will assess the following questions: [1] Is there a valid clinical association 
between the software output and the targeted clinical condition?; [2] Does the 
software correctly process input data to generate accurate, reliable, and precise 
output data?; and [3] Does use of the software’s accurate, reliable, and precise 
output data achieve the intended purpose in the target population in the context of 
clinical care? [53]
Because medical-grade digital health solutions intended to diagnose, treat, or 
prevent a medical condition are subject to FDA scrutiny, the stamp of FDA approval 
is an important designation on which clinicians and organizations can rely in decid-
ing whether to recommend or adopt digital health solutions. Conversely, lower risk 
consumer facing apps that do not make treatment recommendations are not subject 
to FDA enforcement. Thus, clinicians can use these principles, considering patient 
preferences, in recommending digital health apps to their patients.
6. Conclusion
Consumer driven health care is here to stay, and the digital health landscape is 
rapidly evolving to become increasingly consumer facing [54]. Payors are increas-
ingly reimbursing for digital health solutions, especially medical apps that have 
proven effectiveness and that have obtained FDA approval. However, the function-
ality and clinical effectiveness of musculoskeletal digital health solutions varies 
widely. It is thus essential for healthcare providers to assess the available evidence 
supporting effectiveness claims in digital apps. By understanding the MDA land-
scape, healthcare providers can leverage digital health tools to provide optimal 
clinical care to individual patients, and to help manage and prevent musculoskeletal 
injuries on an organizational scale.
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